Mutations within AR impact AR/ligand specificity, which might also contribute to the progression of PCa and the failure of endocrine therapy by allowing AR transcriptional activation in response to antiandrogens or other endogenous hormones. The gene discussed is AR; the disease is posterior cortical atrophy.